| pubmed-article:17931864 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17931864 | lifeskim:mentions | umls-concept:C0001128 | lld:lifeskim |
| pubmed-article:17931864 | lifeskim:mentions | umls-concept:C0908145 | lld:lifeskim |
| pubmed-article:17931864 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:17931864 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:17931864 | pubmed:issue | 23 | lld:pubmed |
| pubmed-article:17931864 | pubmed:dateCreated | 2007-11-6 | lld:pubmed |
| pubmed-article:17931864 | pubmed:abstractText | A new series of non-peptidic, mono-acid protein tyrosine phosphatase 1B (PTP1B) inhibitors has been identified by structure-based design. Compounds with 2-(indol-3-yl)- and 2-phenyl-3,3,3-trifluoro-2-hydroxypropionic acid core units targeted at the enzyme's primary site and a hydrophobic chlorophenylthiazole extension in its 2 degrees site exhibit 3-60microM IC(50)s for PTP1B inhibition in an Sf9 cell-based assay. | lld:pubmed |
| pubmed-article:17931864 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17931864 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17931864 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17931864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17931864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17931864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17931864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17931864 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17931864 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:17931864 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:17931864 | pubmed:author | pubmed-author:SpinksDanielD | lld:pubmed |
| pubmed-article:17931864 | pubmed:author | pubmed-author:MackaySimon... | lld:pubmed |
| pubmed-article:17931864 | pubmed:author | pubmed-author:TakanoYasuoY | lld:pubmed |
| pubmed-article:17931864 | pubmed:author | pubmed-author:AdamsDavid... | lld:pubmed |
| pubmed-article:17931864 | pubmed:author | pubmed-author:MacKenzieSimo... | lld:pubmed |
| pubmed-article:17931864 | pubmed:author | pubmed-author:DickColin A... | lld:pubmed |
| pubmed-article:17931864 | pubmed:author | pubmed-author:MitchellLeeL | lld:pubmed |
| pubmed-article:17931864 | pubmed:author | pubmed-author:JohnstonDerek... | lld:pubmed |
| pubmed-article:17931864 | pubmed:author | pubmed-author:AsanoJunJ | lld:pubmed |
| pubmed-article:17931864 | pubmed:author | pubmed-author:AbrahamAchamm... | lld:pubmed |
| pubmed-article:17931864 | pubmed:author | pubmed-author:JohnstonBlair... | lld:pubmed |
| pubmed-article:17931864 | pubmed:author | pubmed-author:BreslinCather... | lld:pubmed |
| pubmed-article:17931864 | pubmed:author | pubmed-author:IxkesUlrichU | lld:pubmed |
| pubmed-article:17931864 | pubmed:author | pubmed-author:KewnayJustinJ | lld:pubmed |
| pubmed-article:17931864 | pubmed:author | pubmed-author:McFarlaneMora... | lld:pubmed |
| pubmed-article:17931864 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17931864 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:17931864 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:17931864 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17931864 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17931864 | pubmed:pagination | 6579-83 | lld:pubmed |
| pubmed-article:17931864 | pubmed:meshHeading | pubmed-meshheading:17931864... | lld:pubmed |
| pubmed-article:17931864 | pubmed:meshHeading | pubmed-meshheading:17931864... | lld:pubmed |
| pubmed-article:17931864 | pubmed:meshHeading | pubmed-meshheading:17931864... | lld:pubmed |
| pubmed-article:17931864 | pubmed:meshHeading | pubmed-meshheading:17931864... | lld:pubmed |
| pubmed-article:17931864 | pubmed:meshHeading | pubmed-meshheading:17931864... | lld:pubmed |
| pubmed-article:17931864 | pubmed:meshHeading | pubmed-meshheading:17931864... | lld:pubmed |
| pubmed-article:17931864 | pubmed:meshHeading | pubmed-meshheading:17931864... | lld:pubmed |
| pubmed-article:17931864 | pubmed:meshHeading | pubmed-meshheading:17931864... | lld:pubmed |
| pubmed-article:17931864 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17931864 | pubmed:articleTitle | 2-Aryl-3,3,3-trifluoro-2-hydroxypropionic acids: a new class of protein tyrosine phosphatase 1B inhibitors. | lld:pubmed |
| pubmed-article:17931864 | pubmed:affiliation | Department of Chemistry, School of Engineering & Physical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, UK. D.R.Adams@hw.ac.uk | lld:pubmed |
| pubmed-article:17931864 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17931864 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:17931864 | lld:chembl |
